News Sentiment

XBIO sentiment intelligence

Xenetic Biosciences Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 54 Balanced news tone 45 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 2.74 Week of 10 Jul 2026
Weighted tone 54/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

76/100 classification confidence.

Company focus 37

directly relevant articles

Source quality 2

high-authority source matches

Trend context Trend active

-1.3% over one week, -14.5% over four weeks, trend active, and below fair value.

Latest direct headline Neutral

Price to book forward of Xenetic Biosciences, Inc. – NASDAQ:XBIO

Market Reaction

Balanced read

61/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 76/100 classification
One-week reaction -1.3% Price digesting
Trend fit Trend active -14.5% over four weeks
Fair value -22.1% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 14
Neutral 23
Negative 8

Relevance

Why the article matched

Direct first
Direct company coverage 37
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
TradingKey 8
Market source 5
TradingView 4
Stock Titan 4
dars.gov.et 3
Finviz 3
simplywall.st 2
ACCESS Newswire 2

Event Lens

What the news is about

Classified themes
Earnings 21
Market update 19
Analyst action 2
Regulatory and legal 2
Deals and strategy 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 45
TradingView Direct company coverage

Price to book forward of Xenetic Biosciences, Inc. – NASDAQ:XBIO

This page from TradingView displays financial information for Xenetic Biosciences, Inc. (NASDAQ: XBIO), specifically focusing on its "Price to book forward" metric. The content indicates that market data is provided by ICE Data Services, reference data by FactSet, and SEC filings

Tone
Neutral 50/100
Event
Market update
Published
09 Jul 2026 16:10
Source
TradingView
TradingView Direct company coverage

Price to sales forward of Xenetic Biosciences, Inc. – NASDAQ:XBIO

This article provides a financial data point for Xenetic Biosciences, Inc. (NASDAQ: XBIO), specifically its "Price to sales forward" metric. The content indicates that the market was closed at the time of viewing, with no trades apparent. It appears to be a snapshot from a financ

Tone
Neutral 50/100
Event
Market update
Published
09 Jul 2026 04:10
Source
TradingView
Finviz Direct company coverage

XBIO - Xenetic Biosciences Inc Latest SEC Filings

This article provides the latest SEC filings and comprehensive financial overview for Xenetic Biosciences Inc. (XBIO). It includes key financial metrics, performance indicators, insider ownership details, and analyst recommendations. The data highlights the company's valuation, p

Tone
Negative 38/100
Event
Analyst action
Published
04 Jul 2026 10:40
Source
Finviz
Finviz Direct company coverage

XBIO - Xenetic Biosciences Inc Short Interest

This article provides a detailed financial overview and short interest data for Xenetic Biosciences Inc. (XBIO). It includes key metrics such as market capitalization, income, sales, various ratios, and performance indicators spanning different timeframes, along with short intere

Tone
Negative 42/100
Event
Market update
Published
04 Jul 2026 09:40
Source
Finviz
TradingView Direct company coverage

Xenetic Biosciences, Inc. Actuals & Estimates (NASDAQ:XBIO)

This article provides an overview of Xenetic Biosciences, Inc. (NASDAQ: XBIO) financials, including its current stock price, market capitalization, and earnings information. It highlights recent stock performance, historical highs and lows, and key financial metrics like EBITDA a

Tone
Negative 35/100
Event
Earnings
Published
25 Jun 2026 14:10
Source
TradingView
TradingKey Direct company coverage

Xenetic Biosciences Inc (XBIO) Risk Assessment: Volatility, Financial Risk & Investment Risk

Xenetic Biosciences Inc (XBIO) has a current risk assessment score of 1.12, ranking 328 out of 387 in the Biotechnology & Medical Research industry. The company's beta is 2.12, indicating higher volatility compared to the S&P 500. Key risk metrics like maximum drawdown and volati

Tone
Neutral 50/100
Event
Market update
Published
24 Jun 2026 05:39
Source
TradingKey
TradingKey Direct company coverage

Xenetic Biosciences Inc (XBIO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article provides a revenue breakdown for Xenetic Biosciences Inc (XBIO), detailing its business segments, regional revenue, and profit contribution. However, the company has not yet disclosed the relevant data for these categories. The article includes current stock informat

Tone
Neutral 50/100
Event
Earnings
Published
23 Jun 2026 19:39
Source
TradingKey
TradingKey Direct company coverage

Xenetic Biosciences Inc (XBIO) Financial Health: Profitability & Balance Sheet Analysis

Xenetic Biosciences Inc (XBIO) has a robust financial status with a current financial score of 8.34, ranking 48th in the Biotechnology & Medical Research industry. The company reported a significant year-over-year revenue increase of 36.01% to $806.92K and a net profit increase o

Tone
Positive 76/100
Event
Earnings
Published
23 Jun 2026 08:11
Source
TradingKey
TradingKey Direct company coverage

Xenetic Biosciences Inc (XBIO) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Xenetic Biosciences Inc (XBIO), including its price momentum, support and resistance levels, and various technical indicators and moving averages. As of June 26, 2026, XBIO's stock price shows a current momentum score of 6.82 and is t

Tone
Neutral 50/100
Event
Market update
Published
23 Jun 2026 06:40
Source
TradingKey
Simply Wall Street Direct company coverage

Xenetic Biosciences (Nasdaq:XBIO) - Stock Analysis

Xenetic Biosciences (Nasdaq:XBIO) is a biopharmaceutical company focusing on immune-oncology technologies to treat cancers, with a market capitalization of US$6.4 million. The company has reported recent improvements in reducing net losses and growing revenue in its recent quarte

Tone
Negative 38/100
Event
Earnings
Published
21 Jun 2026 04:10
Source
Simply Wall Street
TradingKey Direct company coverage

Xenetic Biosciences Inc (XBIO) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides historical data on dividends and stock splits for Xenetic Biosciences Inc (XBIO). It notes that XBIO has distributed $0.00 in dividends over the past five years and lists stock split events, all of which were a 10-for-1 merger occurring on May 12, 2023. The

Tone
Neutral 50/100
Event
Deals and strategy
Published
19 Jun 2026 08:40
Source
TradingKey
TradingKey Direct company coverage

Xenetic Biosciences Inc (XBIO) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis of Xenetic Biosciences Inc (XBIO), highlighting its current valuation score of 7.62 within the Biotechnology & Medical Research industry. It notes the company's current P/E ratio is -2.53, which is significantly below its recent high. Th

Tone
Neutral 50/100
Event
Market update
Published
18 Jun 2026 11:10
Source
TradingKey
TradingKey Direct company coverage

Xenetic Biosciences Inc (XBIO) Institutional Confidence

Xenetic Biosciences Inc (XBIO) has an institutional shareholding score of 3.00, placing it 193rd out of 388 in the Biotechnology & Medical Research industry. Institutional shareholding proportion decreased by 53.00% quarter-over-quarter to 4.97%. James Simons is the largest insti

Tone
Neutral 50/100
Event
Market update
Published
18 Jun 2026 11:10
Source
TradingKey
TradingKey Direct company coverage

Xenetic Biosciences Inc (XBIO) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for Xenetic Biosciences Inc (XBIO), noting that no earnings forecast score is currently available, unlike the industry average. It also details current stock performance, market capitalization, and various financial metrics. The company

Tone
Neutral 50/100
Event
Earnings
Published
18 Jun 2026 10:39
Source
TradingKey
Moomoo Direct company coverage

Xenetic Biosciences | 8-K: Xenetic Biosciences Reports First Quarter 2026 Financial Results and Highlights Continued Advancement of DNase Oncology Platform

This document is an 8-K filing from Xenetic Biosciences, reporting its financial results for the first quarter of 2026. The filing highlights the continued advancement of the company's DNase Oncology Platform. As an 8-K, it typically contains information deemed material or import

Tone
Positive 70/100
Event
Earnings
Published
06 Jun 2026 22:10
Source
Moomoo
www.marketscreener.com Direct company coverage

Xenetic Biosciences, Inc. Announces That Its Collaboration Partner Received Approval From the Israeli Ministry of Health to Conduct Exploratory, Investigator Initiated Study of DNase I In Combination With Anti-CD19 CAR T Cells in Large B-Cell Lymphoma

Xenetic Biosciences announced that its partner, PeriNess Ltd., received approval from the Israeli Ministry of Health to conduct an exploratory clinical study. This study will combine systemic DNase I with anti-CD19 CAR T cells in patients with large B-cell lymphoma (LBCL). The ap

Tone
Positive 73/100
Event
Regulatory and legal
Published
06 Jun 2026 03:08
Source
www.marketscreener.com
Stock Titan Direct company coverage

Israeli study to combine DNase I with CAR-T in large B-cell lymphoma

Xenetic Biosciences' partner, PeriNess, has received approval from the Israeli Ministry of Health to conduct an exploratory clinical study combining systemic DNase I with anti-CD19 CAR T cells for large B-cell lymphoma (LBCL) patients. The trial, to be conducted at Tel-Aviv Soura

Tone
Positive 66/100
Event
Regulatory and legal
Published
04 Jun 2026 12:39
Source
Stock Titan
BioSpace Direct company coverage

Xenetic Biosciences Showcases Compelling ASCO 2026 Data Demonstrating DNase I Significantly Enhances CAR-T Cell Persistence, Tumor Control, and Survival

Xenetic Biosciences announced positive preclinical data at ASCO 2026, showing that DNase I significantly enhances CAR-T cell expansion, persistence, and antitumor efficacy in aggressive hematologic cancer models. The findings demonstrate DNase I's potential as a transformative ad

Tone
Positive 77/100
Event
Market update
Published
02 Jun 2026 21:09
Source
BioSpace
Investing.com Direct company coverage

Xenetic presents preclinical data on DNase I with CAR-T therapy

Xenetic Biosciences Inc. presented preclinical data showing that DNase I enhances CAR-T cell expansion and antitumor efficacy in hematologic cancer models. The studies demonstrated that DNase I degrades extracellular DNA, preserves CAR-T cell function, and improves tumor control,

Tone
Positive 73/100
Event
Market update
Published
01 Jun 2026 13:09
Source
Investing.com
Stock Titan Direct company coverage

After CAR-T failure, DNase I tied to tumor decline in pediatric lymphoma case

Xenetic Biosciences (NASDAQ: XBIO) presented preclinical and translational data at ASCO 2026 showing that its DNase I significantly improved CAR-T cell expansion, persistence, and tumor control in aggressive B cell malignancy models. The data also include observations from a pedi

Tone
Positive 71/100
Event
Market update
Published
01 Jun 2026 13:09
Source
Stock Titan
Finviz Direct company coverage

XBIO - Xenetic Biosciences Inc Stock Price and Quote

This page provides a comprehensive overview of Xenetic Biosciences Inc. (XBIO) stock, including its latest financial data, recent news, and analyst ratings. It details the company's financial performance, stock statistics, and a chronological list of press releases related to its

Tone
Positive 65/100
Event
Analyst action
Published
30 May 2026 19:39
Source
Finviz
Stock Titan Direct company coverage

Michael Liu and MJL Manager LLC report stakes in Xenetic Biosciences (NASDAQ: XBIO)

Michael Liu and MJL Manager LLC have reported their stakes in Xenetic Biosciences (NASDAQ: XBIO) through a Schedule 13G filing. MJL Manager LLC holds 93,565 shares, representing 4.1% of the class, while Michael Liu individually holds 126,741 shares, accounting for 5.5%. Michael L

Tone
Neutral 50/100
Event
Market update
Published
29 May 2026 19:39
Source
Stock Titan
Bez Kabli Direct company coverage

Xenetic Biosciences Shares Edge Down Ahead of ASCO Update

Xenetic Biosciences shares edged down ahead of its ASCO poster session on June 1, where it will present research on targeting cfDNA and NETs to boost CAR-T cell activity. The company reported improved Q1 results with increased royalty revenue and a narrowed net loss, and is explo

Tone
Negative 38/100
Event
Earnings
Published
22 May 2026 10:05
Source
Bez Kabli
FinancialContent Direct company coverage

Contact Us – Inside INdiana Business - Xenetic Biosciences, Inc. - Common Stock (Nasdaq:XBIO) Stock Quote

This page provides a detailed stock quote and news updates for Xenetic Biosciences, Inc. (Nasdaq: XBIO), showing its current price, trading volume, and performance metrics. It also features recent news releases about the company's financial results, clinical advancements, and col

Tone
Positive 60/100
Event
Earnings
Published
16 May 2026 00:39
Source
FinancialContent